EUVIMEDEUVIMED entdecken
Crossref

Associations between Patterns of Neuroendocrine Liver Metastatic Burden and Outcomes after Liver-Directed Therapy, Systemic Chemotherapy, and Peptide Receptor Radionuclide Therapy

Cathal O Apos Leary, David J Tischfield, Rony Avritscher, Ghassan El-Haddad, Ricardo Garcia-Monaco, Nicholas Fidelman, Namrata Vijayvergia, Pamela L Kunz, Nicholas J Seewald, Michael C Soulen

Neuroendocrinology · 16.04.2026 · 1-13

DOI: 10.1159/000551977 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Neuroendocrinology, online erschienen am 16.04.2026. Verfasst von Cathal O Apos Leary und 9 weiteren Autor:innen. Beteiligte Einrichtung: Division of Vascular and Interventional Radiology, Joint Department of Medical Imaging, University of Toronto, Toronto, Ontario, Canada. Hauptthemen laut MEDLINE: Neuroendocrine Tumors, Liver Neoplasms. Die Arbeit nennt 25 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Treatment selection is a challenge for liver-dominant metastatic neuroendocrine tumors (NETs). Post hoc analysis of NETTER-1 suggested that tumor size but not tumor burden predicted progression-free survival (PFS), contrary to prior publications. Analysis of imaging datasets from capecitabine-temozolomide (CapTem), liver-directed therapy (LDT), and peptide receptor radionuclide therapy (PRRT) cohorts was performed to investigate whether imaging features of liver metastatic disease may guide treatment selection.

Methods

Patients with measurable liver-dominant metastatic NET were identified from imaging datasets from two completed multicenter prospective clinical trials, the capecitabine-temozolomide (CapTem) arm of ECOG-ACRIN 2211 (EA2211) and Randomized Embolization Trial for NeuroEndocrine Tumors (RETNET). A retrospective institutional cohort of consecutive patients treated with PRRT was reviewed for comparison. Extent of liver metastases was categorized by number, maximum diameter, and tumor burden as a fraction of liver volume. These categories were correlated with response category, the primary endpoint, objective response rate (ORR), and PFS by RECIST criteria. Descriptive and graphical analyses were followed by multivariable modeling to test treatment-by-stratum interaction.

Results

A total of 220 patients were included: CapTem (67), LDT (77), and PRRT (76). Pancreatic (62%, 137/220) and bowel primaries predominated (27%, 59/220). Imaging features were not associated with ORR or PFS in any cohort nor the overall population. The ORR for LDT, PRRT, and CapTem were 65%, 38%, and 25%, respectively (p < 0.001). The respective median PFS were LDT 18.9 months (95% CI: 16.3–24), PRRT 21.6 (95% CI: 14.3–26.9), and 16.6 (95% CI: 11.5–29) for CapTem (p = 0.99).

Conclusion

In a review of three distinct cohorts of neuroendocrine tumor patients, no imaging features were identified that predicted treatment outcomes or could inform treatment selection. Further comparative analyses are required prior to using these imaging features to guide treatment selection.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Neuroendocrine TumorsLiver NeoplasmsHumansFemaleMaleMiddle AgedReceptors, PeptideAgedRetrospective StudiesTumor BurdenTreatment OutcomeCapecitabineTemozolomideAdult

Stichwörter der Autor:innen

ChemotherapyEmbolizationNETTER-1Neuroendocrine tumorPeptide receptor radionuclide therapy

Substanzen

Receptors, PeptideCapecitabineTemozolomide

Autor:innen und Institutionen

  • Division of Vascular and Interventional Radiology, Joint Department of Medical Imaging, University of Toronto, Toronto, Ontario, Canada.
  • Division of Nuclear Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA.
  • Department of Interventional Radiology, MD Anderson Cancer Center, Houston, Texas, USA.
  • Department of Radiology, Moffitt Cancer Center, Tampa, Florida, USA.
  • Department of Radiology, Hospital Italiano, Bueno Aires, Argentina.
  • Division of Interventional Radiology, UCSF, San Francisco, California, USA.

Zitieren

APA

O Apos Leary, C., Tischfield, D. J., Avritscher, R., El-Haddad, G., Garcia-Monaco, R., Fidelman, N., Vijayvergia, N., Kunz, P. L., Seewald, N. J., & Soulen, M. C. (2026). Associations between Patterns of Neuroendocrine Liver Metastatic Burden and Outcomes after Liver-Directed Therapy, Systemic Chemotherapy, and Peptide Receptor Radionuclide Therapy. Neuroendocrinology, 1-13. https://doi.org/10.1159/000551977

Vancouver

O Apos Leary C, Tischfield DJ, Avritscher R, El-Haddad G, Garcia-Monaco R, Fidelman N, et al. Associations between Patterns of Neuroendocrine Liver Metastatic Burden and Outcomes after Liver-Directed Therapy, Systemic Chemotherapy, and Peptide Receptor Radionuclide Therapy. Neuroendocrinology. 2026:1-13. doi:10.1159/000551977

BibTeX
@article{OAposLeary2026,
  author = {O Apos Leary, Cathal and Tischfield, David J and Avritscher, Rony and El-Haddad, Ghassan and Garcia-Monaco, Ricardo and Fidelman, Nicholas and Vijayvergia, Namrata and Kunz, Pamela L and Seewald, Nicholas J and Soulen, Michael C},
  title = {Associations between Patterns of Neuroendocrine Liver Metastatic Burden and Outcomes after Liver-Directed Therapy, Systemic Chemotherapy, and Peptide Receptor Radionuclide Therapy},
  journal = {Neuroendocrinology},
  year = {2026},
  pages = {1--13},
  doi = {10.1159/000551977}
}
Kostenlos starten →